Provera tablet 100mg Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

provera tablet 100mg

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: isopropyl alcohol; maize starch; purified water; gelatin; sodium starch glycollate; sodium benzoate; magnesium stearate; microcrystalline cellulose; macrogol 400; docusate sodium - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

DEPO-MEDROL 40 MG/ML INJECTABLE CORTICOSTEROID Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

depo-medrol 40 mg/ml injectable corticosteroid

zoetis australia pty ltd - methylprednisolone acetate - parenteral liquid/solution/suspension - methylprednisolone acetate steroid-glucocorticoid active 40.0 mg/ml - endocrine system - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - corticosteroid | advancing parturition | allergic reactions | antiadrenal suppression | anti-inflammatory | antishock | arthritis | bronchitis | catabolic complications | chronic bronchitis | corticosteroids | corticosteroids and relate | coughs | dermatitis | dermatological disorders | dermatoses | eczema | glucogenic steroid | joint disease | ketosis | locomotive diseases | musculo skeletal inflammat | orthopaedic | parturient udder oedema | parturition | pruritis | respiratory tract diseases | rheumatic diseases | stress | toxaemia | water retention

RALOVERA Medroxyprogesterone acetate 5mg tablet Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

ralovera medroxyprogesterone acetate 5mg tablet

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: calcium stearate; liquid paraffin; sucrose; lactose monohydrate; indigo carmine; maize starch; purified talc - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2.endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding, in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

PROVERA Medroxyprogesterone acetate 5mg tablet Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

provera medroxyprogesterone acetate 5mg tablet

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

PROVERA Medroxyprogesterone acetate 2.5mg tablet Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

provera medroxyprogesterone acetate 2.5mg tablet

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.